Steven Robinette
Investitore di Private Equity presso Atlas Venture Advisors, Inc.
Posizioni attive di Steven Robinette
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Atlas Venture Advisors, Inc.
 Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Investitore di Private Equity | 01/09/2015 | - |
Storia della carriera di Steven Robinette
Precedenti posizioni note di Steven Robinette
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| VIGIL NEUROSCIENCE, INC. | Investitore di Private Equity | - | - |
Korro Bio, Inc.
 Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Investitore di Private Equity | - | - |
Disarm Therapeutics, Inc.
 Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Investitore di Private Equity | - | - |
Disc Medicine Opco, Inc.
 Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | Investitore di Private Equity | - | - |
| KYMERA THERAPEUTICS, INC. | Investitore di Private Equity | - | - |
Formazione di Steven Robinette
| Imperial College London | Doctorate Degree |
| University of Florida | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 8 |
| Regno Unito | 2 |
Posizioni
| Private Equity Investor | 6 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 6 |
| Consumer Services | 3 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| KYMERA THERAPEUTICS, INC. | Health Technology |
| VIGIL NEUROSCIENCE, INC. | Health Technology |
| Aziende private | 4 |
|---|---|
Atlas Venture Advisors, Inc.
Atlas Venture Advisors, Inc. Investment ManagersFinance Atlas Venture Advisors Inc (Atlas Venture Advisors) is a venture capital firm founded in 1980 by Christopher Julian Spray. The firm is headquartered in Cambridge, Massachusetts. | Finance |
Disarm Therapeutics, Inc.
Disarm Therapeutics, Inc. BiotechnologyHealth Technology Disarm Therapeutics, Inc. engages in the development of therapeutics to treat patients with neurological diseases. It includes multiple sclerosis, amyotrophic lateral sclerosis, glaucoma, and peripheral neuropathies. The company was founded by Jason Rhodes, Jeffrey Milbrandt, Raul Krauss, Aaron DiAntonio, and Rajesh Devraj on October 21, 2016 and is headquartered in Cambridge, MA. | Health Technology |
Disc Medicine Opco, Inc.
Disc Medicine Opco, Inc. BiotechnologyHealth Technology Disc Medicine, Inc. engages in the development of therapies addressing ineffective red blood cell production in hematologic diseases. Its product pipeline includes anti-hemojuvelin antibody and Matriptase-2 inhibitor. The company was founded by Brian MacDonald and is headquartered in Cambridge, MA. | Health Technology |
Korro Bio, Inc.
Korro Bio, Inc. BiotechnologyHealth Technology Korro Bio, Inc. engages in the development of a bio therapeutics. It focuses on a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues. The company was founded by Jean-Fran?ois Formela, Josh Rosenthal, Nessan Bermingham, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Steven Robinette
- Esperienza
